Kura Oncology Inc Net Income per Employee (KURA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Kura Oncology Inc   (NASDAQ: KURA)
 

Kura Oncology Inc Net Income per Employee

KURA's Quarterly Results, Trends, Rankings, Statistics
Kura Oncology Inc recorded a cumulative net loss of $-297 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 240 other companies achieving higher income per employee. While Kura Oncology Inc 's total ranking has deteriorated compared to the previous quarter from 3596 to 3767.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KURA Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,141,442 -1,132,962 -1,071,792 -834,169 -758,354
KURA's Total Ranking # 3767 # 3596 # 3513 # 1499 # 2317
Seq. Net Income Change - - - - -

KURA Company Profile >> Back to KURA Efficiency Comparisons >> Compare KURA Net Income per Employee to its Competitors

KURA Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 241
Healthcare Sector # 626
Overall Market # 3767

Net Income per Employee Statistics
High Average Low
$ -105 $ -333,267 $ -1,141,442
(Dec 31 2012)   (Jun 30 2026)




  News about Kura Oncology Inc Income per employee

Kura Oncology Grants Inducement Awards to New Employees in Compliance with Nasdaq Rule 5635(c)(4)


Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, recently announced the granting of inducement awards to two new employees. The Compensation Committee of the company s Board of Directors approved the issuance of nonstatutory stock options to purchase 93,000 shares of common stock as part of the 2023 Inducement Option Plan. These stock options were deemed essential to attracting and retaining key talent, in line with Nasdaq Listing Rule 5635(c)(4).
Despite these inducement grants, Kura Oncology Inc has faced financial challenges, recording a cumulative net loss of $-143 million in the 12 months leading up to the third quarter of 2023. Additionally, data shows that employees of 98 other companies in the Major Pharmaceutical Preparations industry have seen higher income per employee growth, indicating increased competition and pressure within the sector.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-12T06:19:57+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.